Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Immunome, Inc.NASDAQ: IMNM
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit turns positive
Q3 FY2026 gross profit was $0, compared with -$49.19M a year earlier. Trailing-twelve-month gross profit was -$753K.
Context
- Gross profit amounted to 57.4% of revenue in FY2025, down 42.6 pp from a year earlier.
- Gross profit increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$188.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 3.99M USD
- Year-over-year change
- -55.9%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.99M | -55.9% |
| FY2024 | 2024-12-31 | 9.04M | -35.5% |
| FY2023 | 2023-12-31 | 14.02M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Gross Profit vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +98.1% is the 2nd highest of 7, against a peer median of +34.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $381.15M USD | +15.4% | +28.0% | 98.8% | |
| LTM Mar 2026 | $109.85M USD | +16.2% | -9.3% | 69.9% | |
| LTM Mar 2026 | $98.33M USD | +52.1% | +17.0% | 98.7% | |
| LTM Mar 2026 | €37.3M EUR | -74.1% | -9.9% | 100.0% | |
| LTM Sep 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | -$55K USD | — | — | — | |
| LTM Mar 2026 | -$130.77K USD | — | — | — | |
| LTM Sep 2026 | -$742K USD | +99.6% | — | 662.5% | |
| LTM Sep 2026 | -$753K USD | +98.1% | — | — | |
| LTM Mar 2026 | -$7.53M USD | +94.3% | +71.2% | 11.9% | |
| Peer median (excluding IMNM) | — | +34.2% | +17.0% | 98.8% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.